0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Successful Anticoagulation for Bilateral Central Retinal Vein Occlusions Accompanied by Cerebral Venous Thrombosis FREE

Young Hoon Lee, MD; Joon Young Lee, MD; Ye Sung Kim, MD; Dae Hyun Kim, MD; Jei Kim, MD, PhD
[+] Author Affiliations

Author Affiliations: Department of Neurology, Chungnam National University Hospital, Taejon, Korea.


Arch Neurol. 2006;63(11):1648-1651. doi:10.1001/archneur.63.11.1648.
Text Size: A A A
Published online

ABSTRACT

Background  Concurrent development of retinal venous drainage and cerebral venous thrombosis has not been reported.

Case Description  We describe a 23-year-old man with bilateral central retinal vein occlusions and cerebral venous thrombosis. Initially observed bilateral hemorrhagic retinopathy and thrombus in the right transverse sinus of the patient began to resolve after 2 weeks of low-molecular-weight heparin. Hemorrhagic retinopathy progressively improved to previous visual acuity and the right lateral sinus remained patent by maintenance of anticoagulation with warfarin.

Conclusion  The present case shows effectiveness of low-molecular-weight heparin for the initial management of hemorrhagic retinopathy of central retinal vein occlusion combined with cerebral venous thrombosis.

Figures in this Article

Central retinal vein occlusion (CRVO) is induced by thrombosis and altered venous drainage of the central retinal vein.1 The central retinal vein drains into the intracranial venous system through the cavernous sinus. Concurrent development of CRVO and intracranial venous thrombosis (CVT) has not been documented. We describe a young man who suffered from the simultaneous development of bilateral CRVO and CVT. The use of anticoagulants, particularly unfractionated heparin, for the management of CRVO is highly controversial.2,3 Hemorrhagic retinopathy of the CRVO and CVT in our patient was successfully managed using low-molecular-weight heparin (LMWH) without hemorrhagic adverse effects.

CASE REPORT

A 23-year-old man with a history of hypertension and pulmonary embolism was admitted to the neurology department with foggy vision in both eyes and a headache. The visual disturbances had developed 5 days before admission and were aggravated over the course of time. At admission, visual acuity of the patient was down to 20/40 OD and 20/100 OS, from a previous acuity of 20/15 OU. On funduscopic examination, marked optic disc swelling and retinal hemorrhages were observed in both eyes, suggesting the possibility of CRVO (Figure 1A and B). The patient also complained of a headache. However, nothing abnormal was found during physical and neurological examinations. On initial preenhanced and postenhanced T1-weighted images and magnetic resonance venograms, a thrombus in the right transverse sinus was observed (Figure 2A and B).

Place holder to copy figure label and caption
Figure 1.

Initial and follow-up funduscopic findings. Initially observed marked optic disc swelling and retinal hemorrhage on both fundi (A and B) were progressively improved 2 weeks after completion of low-molecular-weight heparin (LMWH) treatment (C and D) and maintenance with warfarin (E and F).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Initial and follow-up magnetic resonance imaging and magnetic resonance venogram (MRV) findings. Initial thrombus (A and B; arrows) and disturbed patency (C; arrow) of the right lateral sinus was recovered 2 weeks after completion of low-molecular-weight heparin (LMWH) (D, E, and F; arrows) and after maintenance with warfarin (G, H, and I; arrows). T1WI indicates T1-weighted images.

Graphic Jump Location

Complete blood cell count revealed an increased hemoglobin level of 18.0 g/dL (normal range, 13.5-17.5 g/dL), with no associated abnormal findings on leukocyte or platelet counts. Of the hemostasis-related workups—which included antiphospholipid antibody, protein C and S antigens and activity, lupus anticoagulant, anticardiolipin antibody, antithrombin III, rheumatoid factor, and homocysteine—only the protein C antigen level was decreased to 62.39% (normal range, 72%-160%). No abnormal findings were observed in liver or renal function tests.

The patient had taken warfarin (9 mg/d) to prevent recurrence of pulmonary thromboembolism, which developed and was managed 5 months prior to admission. At admission, the patient showed no clinical or laboratory evidence suggesting deep vein thrombosis or pulmonary thromboembolism. However, the international normal range for prothrombin time level (1.639), checked at admission, was lower than the therapeutic range of 2 to 3.

Subcutaneous injection of 7500 IU of nadroparin (Fraxiparine; Sanofi-Aventis, Paris, France) was administered twice a day from the second day after admission and was maintained for 2 weeks. After the nadroparin regimen, warfarin treatment was maintained to within 2 to 3 of the prothrombin time (international normal range). The headache subsided the first day after treatment with nadroparin. The foggy bilateral vision started to become clear on the second day after treatment with nadroparin began. The hemorrhagic retinopathy and optic disc swelling were slightly improved without hemorrhagic aggravation by the nadroparin regimen (Figure 1C and D), and visual acuity was also enhanced to 20/20 OD and 20/50 OS. The thrombus in the right lateral sinus was resolved on follow-up with T1-weighted images and magnetic resonance venograms taken at the completion of the nadroparin schedule (Figure 2C and D). After the change from anticoagulation to warfarin, visual acuity progressively improved. On the last visual acuity evaluation performed 2 months after being treated with warfarin, the patient's visual acuity in both eyes recovered to near their previous levels of 20/15 OD and 20/20 OS. Retinal hemorrhages and optic disc swelling were also markedly improved on follow-up funduscopic examination (Figure 1E and F). In addition, the patency of the right lateral sinus was preserved (Figure 2E and F).

COMMENT

The present description is the first case of simultaneous bilateral CRVO accompanied by CVT to be reported. Bilateral involvement is observed in 7.7% to 19% of all CRVO patients.2,4 However, simultaneous bilateral CRVO involvement has rarely been reported in Waldenstrom macroglobulinemia5 and multiple myeloma.6 Our simultaneous bilateral CRVO patient had different causes of low protein C antigen and high hemoglobin levels. Interestingly, this CRVO patient also had CVT in the right lateral sinus at the start of the visual alterations. Distinctive signs of cavernous thrombosis, such as chemosis, proptosis, and ophthalmoplegia, were not observed in this case. Thrombus in the cavernous sinus could not be verified by magnetic resonance imaging or magnetic resonance venogram evaluations. However, thrombus in the right lateral sinus was evidence of the disturbances in the intracranial venous drainage system. Therefore, disturbed intracranial venous drainage might be another cause of the bilateral CRVO in this patient.

Because of the natural course of CRVO, particularly when the ischemic type is involved, permanent visual complications were expected as a result of secondary macular degeneration and/or neovascularization.2 Thus, rapid restoration of venous drainage might be an important therapeutic issue to prevent a poor outcome of CRVO. Medical and surgical management, as well as panretinal photocoagulation, has been advocated to improve venous drainage and decrease intraocular pressure for CRVO.2 In our present case, because bilateral CRVO was combined with CVT, surgical and photocoagulation management for the CRVO could not be selected to improve intracranial venous drainage. Unfractionated heparin could be a choice to restore venous drainage caused by CRVO3 and CVT,7 especially when they are induced by coagulation disturbances, as in our case. However, the increasing likelihood of hemorrhage was the main restriction in recommending unfractionated heparin as a first-line drug for the management of CRVO2 and CVT.7 In particular, if remarkable hemorrhagic conversions were associated with the ischemic retinopathy, the hemorrhagic risk associated with unfractionated heparin could be a major restriction for the initial anticoagulation for CRVO3 and CVT.7

Low-molecular-weight heparin is an alternative anticoagulant that has a low hemorrhagic risk, beneficial bioavailability, and easy subcutaneous administration.8 The beneficial effects of LMWH have been reported in the management of CVT.9 In particular, LMWH was safe and effective for managing hemorrhagic-converted venous infarctions without aggravating initial hemorrhages.9,10 In our patient, follow-up magnetic resonance imaging studies showed improvement of venous thrombus. Interestingly, visual acuity and hemorrhagic retinopathy caused by CRVO also started to improve in a few days without hemorrhagic aggravation after beginning LMWH. The initial improvement of the retinopathy continued progressively after anticoagulation treatment was changed to warfarin.

In conclusion, the successful effect of LMWH on our CRVO and CVT patient showed the possibility of using LMWH for the management of CRVO with intracranial venous drainage disturbances.

ARTICLE INFORMATION

Correspondence: Jei Kim, MD, PhD, Department of Neurology, Chungnam National University Hospital, 640 Daesa-dong, Joong-ku, Taejon 301-721, South Korea (jeikim@cnu.ac.kr).

Accepted for Publication: June 16, 2006.

Author Contributions:Study concept and design: Y. Lee and J. Kim. Acquisition of data: Y. Lee and J. Lee. Analysis and interpretation of data: Y. Lee, Y. Kim, D. Kim, and J. Kim. Drafting of the manuscript: Y. Lee, J. Lee, Y. Kim, and J. Kim. Critical revision of the manuscript for important intellectual content: D. Kim and J. Kim. Administrative, technical, and material support: Y. Lee, J. Lee, and Y. Kim. Study supervision: J. Kim.

Financial Disclosure: None reported.

REFERENCES

Williamson  TH Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997;81698- 704
PubMed Link to Article
Hayreh  SS Management of central retinal vein occlusion. Ophthalmologica 2003;217167- 188
PubMed Link to Article
Prisco  DMarcucci  R Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002;32308- 311
PubMed Link to Article
Opremcak  EMRehmar  AJRidenour  CDKurz  DE Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006;26297- 305
PubMed Link to Article
Casares  PZGillet  DSVerity  DHRowson  NR Bilateral simultaneous central retinal vein occlusion (CRVO) caused by waldenstrom's macroglobulinaemia with acquired von willebrand's disease. Br J Haematol 2002;118344- 347
PubMed Link to Article
Aggio  FBCariello  AJAlmeida  MS  et al.  Bilateral central retinal vein occlusion associated with multiple myeloma. Ophthalmologica 2004;218283- 287
PubMed Link to Article
Stam  J Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;3521791- 1798
PubMed Link to Article
Weitz  JI Low-molecular-weight heparins. N Engl J Med 1997;337688- 698
PubMed Link to Article
de Bruijn  SFStam  J Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30484- 488
PubMed Link to Article
Kim  JSJeong  SHKim  DHKim  J Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis. J Clin Neurol 2005;1134- 141
Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Initial and follow-up funduscopic findings. Initially observed marked optic disc swelling and retinal hemorrhage on both fundi (A and B) were progressively improved 2 weeks after completion of low-molecular-weight heparin (LMWH) treatment (C and D) and maintenance with warfarin (E and F).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Initial and follow-up magnetic resonance imaging and magnetic resonance venogram (MRV) findings. Initial thrombus (A and B; arrows) and disturbed patency (C; arrow) of the right lateral sinus was recovered 2 weeks after completion of low-molecular-weight heparin (LMWH) (D, E, and F; arrows) and after maintenance with warfarin (G, H, and I; arrows). T1WI indicates T1-weighted images.

Graphic Jump Location

Tables

References

Williamson  TH Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997;81698- 704
PubMed Link to Article
Hayreh  SS Management of central retinal vein occlusion. Ophthalmologica 2003;217167- 188
PubMed Link to Article
Prisco  DMarcucci  R Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002;32308- 311
PubMed Link to Article
Opremcak  EMRehmar  AJRidenour  CDKurz  DE Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006;26297- 305
PubMed Link to Article
Casares  PZGillet  DSVerity  DHRowson  NR Bilateral simultaneous central retinal vein occlusion (CRVO) caused by waldenstrom's macroglobulinaemia with acquired von willebrand's disease. Br J Haematol 2002;118344- 347
PubMed Link to Article
Aggio  FBCariello  AJAlmeida  MS  et al.  Bilateral central retinal vein occlusion associated with multiple myeloma. Ophthalmologica 2004;218283- 287
PubMed Link to Article
Stam  J Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;3521791- 1798
PubMed Link to Article
Weitz  JI Low-molecular-weight heparins. N Engl J Med 1997;337688- 698
PubMed Link to Article
de Bruijn  SFStam  J Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999;30484- 488
PubMed Link to Article
Kim  JSJeong  SHKim  DHKim  J Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis. J Clin Neurol 2005;1134- 141
Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com